[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: In order to minimize any bias between groups as a general policy, all patients will only receive lopinavir/retonavir (Kaletra\u00ae) and corticosteroids as their treatment regimen for COVID-19. Antibiotic medications use will be limited as much as possible and will only be used in each specific case based on the diagnosis of the infectious specialist or intensivist when necessary. On the second day of hospital admission, the intervention group will initially receive a single intravenous bolus of 1 mg/kg (1% solution) of methylene blue administered over 20-60 minutes. The patients will then be given 0.25 mg/kg per hour dose of methylene bluefor 24 hours. Methylene blue has a commercial name of METIBLO and generic name of Methylthioninium chloride . Each 1ml ampule contains 10 mg methylthionium chloride. It is made in Belgium by Oterop company.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: These patients will only receive lopinavir/retonavir (Kaletra\u00ae) and corticosteroids as their treatment regimen for COVID-19. Antibiotic medications use will be limited as much as possible and will only be used in each specific case based on the diagnosis of the infectious disease specialist or emergency medicine specialist when necessary.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 797, "treatment_name": "Methylene blue", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]